Global Needle-free Drug Delivery Devices Market

Needle-free Drug Delivery Devices Market Size, Share, Growth Analysis, By Technology(Jet injectors, Transdermal patches, and Inhalation-based systems), By End-user(Hospitals and Clinics to Home Healthcare Settings), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35I2250 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 61 | Figures: 74

Needle-free Drug Delivery Devices Market Insights

Global Needle-free Drug Delivery Devices Market size was valued at USD 13.99 Billion in 2022 and is poised to grow from USD 14.94 Billion in 2023 to USD 25.29 Billion by 2031, at a CAGR of 6.8% during the forecast period (2024-2031).

The healthcare industry can be transformed thanks to the global needle-free drug delivery devices market. Its pivotal role in potentially changing the healthcare sector for good has driven its growth in recent times. The market has gone through a period of substantial growth. These devices erase the need for traditional needles in administration of drugs. It removes the risk of needle-related issues and reduces patient pain entirely.

The healthcare sector is seeking pain-free and patient friendly methods of drug administration. This demand is prevalent in cases of chronic illnesses like autoimmune disorders and diabetes. This need has fueled market growth. Other factors that drive market expansion are the need for self-injected medications and the increasing geriatric populace.

Transdermal patches and jet injectors are some of the innovative technologies that have been developed by the medical field. These segments have largely contributed to market growth. The precision and convenience they offer have fueled their popularity in the market.

Healthcare facilities have typically led the end-user category in the market. This segment prioritizes the comfort of the patient and wants to offer painless drug administration in exchange for their compliance. This has helped the segment retain its place in the market. However, homecare settings are quickly gaining traction in the market.

The market is also experiencing substantial growth with new technologies flowing into the market. These include inhalable drug delivery systems, along with jet injectors and transdermal patches. The growing emphasis on patient comfort and care has served the demand for needle-free drug delivery. Conversely, market growth can be inhibited due to high expensive development costs and regulatory issues.

The evolution of the healthcare sector across the globe ensures the continued expansion of this market. The needle-free drug delivery devices market has the potential to improve efficiency of drug delivery and enhance patient care.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Needle-free Drug Delivery Devices Market size was valued at USD 13.99 Billion in 2022 and is poised to grow from USD 14.94 Billion in 2023 to USD 25.29 Billion by 2031, at a CAGR of 6.8% during the forecast period (2024-2031).

The needle-free drug delivery devices market is defined by its competitive environment. This landscape includes all market players striving to gain the largest market share. This intense competition has driven the market’s growth. Some industry leaders include 3M, Pfizer, Johnson & Johnson, and Medtronic. These companies dominate the market. They have achieved this by using their best advantages. They include tremendous R&D efforts and a wide range of products. 'Becton, Dickinson and Company (BD) (USA)', 'Zogenix (USA)', 'Pfizer Inc. (USA)', 'Bespak Europe Ltd. (UK, a subsidiary of AptarGroup)', 'Janssen Pharmaceuticals (Belgium, subsidiary of Johnson & Johnson)', 'PharmaJet (USA)', '3M (USA)', 'National Medical Products Inc. (NMP Pharma) (USA)', 'Antares Pharma (USA)', 'Crossject (France)', 'Novartis AG (Switzerland)', 'Bioject Medical Technologies Inc. (USA)', 'Pharmajet (USA)', 'Astrazeneca (UK)', 'Eli Lilly and Company (USA)', 'MedImmune (USA, a subsidiary of AstraZeneca)', 'Genentech (USA, a subsidiary of Roche)', 'Inovio Pharmaceuticals (USA)', 'Valeritas (USA)'

Advancements in Technology: The market has seen the entry of new devices which are more precisely efficient. This is because of the continuous improvements in needle-free drug delivery technology. The introduction of advanced devices like transdermal patches, along with micro-needles and jet injectors, has been made possible with this development. These new technologies can be applied to many cases. These tools are only becoming more precise and are suited to varying applications as technology keeps developing.

Expanding Applications in Healthcare: The market was witnessing a notable trend. Drug delivery devices that didn’t use needles could be applied elsewhere apart from traditional insulin and vaccines delivery. The market also served specialized therapeutics and biologic in addition to its previous purposes. Technological advancements can be credited for the use of these devices in additional applications. As the requirement for controlled and accurate drug administration persists, the market can expect further innovations and uses.

The market’s dominant region is North America. Its increased usage of innovative technologies in the field of medicine and a well-established healthcare infrastructure has steeled its top market position. Other factors that contribute to North America’s supremacy are its supportive regulatory framework and continuous R&D efforts.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Needle-free Drug Delivery Devices Market

Report ID: SQMIG35I2250

$5,300
BUY NOW GET FREE SAMPLE